Sébastien Anguille
Sébastien Anguille is an expert in Hematology at Antwerp University Hospital (Belgium). Sébastien Anguille has authored 156 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 9 of them ongoing. SLR score: 923 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2008 - 2026
Number : 156
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Inflammatory mechanisms in the AML bone marrow niche: From pathogenesis to therapy. PMID 42594808 — cytokines, cells, hematopoiesis, bone marrow, neoplasms, clonal hematopoiesis, therapeutics | Cytokine Growth Factor Rev | 2026 | 0 |
| CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study. PMID 42660131 — cells, safety, hodgkin disease, lymphoma, lymphoma, large b-cell, diffuse, neutropenia, drug-related side effects and adverse reactions, lymphoma, non-hodgkin, therapeutics, t-lymphocytes, veins, b-lymphocytes, hematologic diseases, thrombocytopenia, car-t cell | Lancet Haematol | 2026 | 0 |
| Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway. PMID 42592017 | TH Open | 2026 | 0 |
| Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy. PMID 42367083 — pharmaceutical preparations, leukemia, leukemia, myeloid, acute, immunotherapy, leukemia, myeloid, proteomics, precision medicine, therapeutics | Technol Cancer Res Treat | 2026 | 0 |
| The search for safe and effective CAR-T targets in AML. PMID 42321183 — cells, blood, microscopy, electron, scanning transmission, neoplasms, stem cells, blood cells, therapeutics | Blood Cancer J | 2026 | 0 |
Clinical Studies 23
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A long term follow up study for patients treated with Galapagos CAR T cell therapies 2023-510173-34-00 — cells, hodgkin disease, follow-up studies, lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, multiple myeloma, lymphoma, non-hodgkin, therapeutics, t-lymphocytes, b-lymphocytes, car-t cell | Phase 3 | Recruiting | 2024 |
| Phase 1 First in Human Study of JNJ 95566692 in Participants with NHLs 2025-523297-16-00 | Phase 1 | Recruiting | 2026 |
| A First in Human Dose Escalation Study of JNJ 79635322 in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis 2023-503679-12-00 — multiple myeloma, amyloidosis, immunoglobulin light-chain amyloidosis | Phase 1 | Recruiting | 2022 |
| A Multi arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma 2023-503440-14-00 — multiple chronic conditions, multiple myeloma, therapeutics | Phase 1 | Active not recruiting | 2021 |
| A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal DP) or Talquetamab SC in Combination With Daratumumab SC (Tal D) Versus Daratumumab SC Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy 2023-503467-41-00 — dexamethasone, multiple myeloma, therapeutics | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map